Table 3.

Effects of Tirofiban treatment on functional outcomes in patients with different ischemic stroke etiology.

	Tirofiban	Without tirofiban	P value	Adjusted OR (95% CI) and P value
ALL PATIENTS*
3-mo mRS, 0-1	22/71 (31.0)	21/124 (16.9)	0.023	2.087 (0.902–4.827), 0.086
3-mo mRS, 0-2	30/71 (42.3)	36/124 (29.0)	0.060	1.862 (0.913–3.800), 0.087
3-mo mRS, 6	15/71 (21.1)	41/124 (33.1)	0.076	0.538 (0.256–1.133), 0.103
LARGE ARTERY ATHEROSCLEROSIS#
3-mo mRS, 0-1	18/39 (46.2)	11/56 (19.6)	0.006	3.050 (0.969–9.598), 0.057
3-mo mRS, 0-2	21/39 (53.8)	16/56 (28.6)	0.013	2.281 (0.813–6.401), 0.117
3-mo mRS, 6	8/39 (20.5)	20/56 (35.7)	0.110	0.444 (0.145–1.359), 0.155
CARDIOEMBOLISM$
3-mo mRS, 0-1	2/28 (7.1)	9/56 (16.1)	0.322	0.719 (0.107–4.807), 0.733
3-mo mRS, 0-2	7/28 (25.0)	18/56 (32.1)	0.500	0.945 (0.276–3.232), 0.928
3-mo mRS, 6	6/28 (21.4)	13/56 (23.2)	0.854	0.722 (0.202–2.577), 0.616

^*Adjusted for age, gender, NIHSS on admission, previous TIA/stroke, intravenous thrombolysis.

^#Adjusted for age, gender, NIHSS on admission, smoking, diabetes mellitus.

^$Adjusted for age, gender, NIHSS on admission, smoking, previous TIA/stroke, intravenous thrombolysis.

mRS indicates modified Rankin Scale.